The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
First update on cryptococcus in the era of antiretroviral treatment expansion reveals disproportionate burden in sub-Saharan Africa and a need for better treatment options.
In the era of highly active antiretroviral treatment, HIV-associated neurocognitive disorders (HAND) still affect people living with HIV as they get older
A lack of male involvement in their partner’s HIV treatment programme before and after pregnancy has been found to be one of the biggest challenges to retaining women in HIV care in Malawi.
Just over a year since launch, a new mobile app is helping Kenya track progress, plan and allocate resources for the HIV response, providing useful learning for other countries.
‘Surprising’ research from Conference on Retroviruses and Opportunistic Infections (CROI) shows drug resistance does not impact test-and-treat roll-out in South Africa – at least in the short term.
HIV is more proactively monitored among urban HIV patients than rural patients, and drug resistance and treatment failure is less prevalent. However outcomes for second line treatment remain similar.
Understanding the vaginal microbiome and how it impacts HIV risk could help develop more effective treatment and prevention strategies for young women in sub-Saharan Africa.
Treatment scale-up has had major public health benefits. But where resources are scarce, interventions to keep people in care could be more cost-effective than moving to treat everybody living with HIV after diagnosis.
Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.